According to the Association of the British Pharmaceutical Industry, it costs £1.12 billion and up to 12 years to develop a single drug. Kenneth Mulvany, founder of BenevolentAI, the largest privately held artificial intelligence company in Europe, wondered whether AI could speed this up, to create more cures for previously thought incurable diseases. Drug discovery is, after all, a complicated business. The problem is making sense of the enormous amounts of data available to help researchers better inform the process.

Drug discovery is, after all, a complicated business.  And one of the challenges is making sense of the enormous amounts of data available to help researchers better inform the process.

Kenneth will be in conversation with Manu Gupta, Hot Topics Contributing Editor, and the series lead for Life In 2030.